Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis. Cancer cells can secrete pro-angiogenic factors like VEGF (vascular endothelial growth factor) to stimulate the formation of new blood vessels, ensuring a sufficient supply of oxygen and nutrients. Inhibiting angiogenesis has been a target for cancer therapy, with drugs like bevacizumab (an anti-VEGF antibody) showing some success in treating various cancers.
